Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Journal of Biomedicine and Translational Research Indonesian Journal of Pharmaceutical Science and Technology
Nursyafillah, Rizki Noval
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Computer Science & IT Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Anti-Inflammatory and Photoprotective Potential of Clitoria ternatea Extract in Mitigating UV-B-Induced IL-1β Elevation Damayanti, Galih Sari; Kresnantio, Febryan Fadhil; Mahadewa, Narendra Lintang; Nursyafillah, Rizki Noval; Fany, Alfa Sofia
Journal of Biomedicine and Translational Research Vol 12, No 1 (2026): April 2026
Publisher : Faculty of Medicine, Universitas Diponegoro

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/jbtr.v12i1.31148

Abstract

ABSTRACTBackground: Global climate change has escalated ultraviolet (UV) radiation exposure, contributing to skin aging and damage. Ultraviolet radiation, especially UV-B, is a known inducer of reactive oxygen species (ROS), which trigger inflammation and accelerate photoaging by increasing IL-1, IL-6, IL-8, and TNF-α levels. Clitoria ternatea, or butterfly pea, contains bioactive phytochemicals such as flavonoids and anthocyanins, known for their antioxidant and anti-inflammatory properties.Objective: This study aims to evaluate the effects of C. ternatea extract cream on serum IL-1β levels in UV-B-induced Wistar rats, exploring its potential in reducing photoaging and promoting skin health.Methods: True experimental study with post-test only control group design involving male Wistar rats for 30 days. The rats were divided into four groups: negative control with placebo (base cream) and treatment groups given 2.5%, 5%, and 10% C. ternatea extract cream, with UV-B induction applied for 30 minutes, three times per week. IL-1β were evaluated using ELISA Rat IL-1 kit.Results: Significant differences were observed between the negative control and extract-treated groups. The lowest IL-1β levels were recorded in the 2.5% and 5% extract groups (p<0.001), indicating a strong anti-inflammatory effect. The findings suggest that C. ternatea extract cream, especially at 2.5% and 5% concentrations, effectively reduces IL-1β levels in UV-B-induced Wistar rats. The bioactive compounds in C. ternatea, such as anthocyanins and flavonoids, may inhibit ROS production and inflammation pathways. This study demonstrates that C. ternatea extract cream can reduce IL-1β levels, potentially mitigating UV-induced skin damage.Conclusion: The C. ternatea extract’s anti-inflammatory properties make it a promising candidate for skincare products aimed at reducing photoaging. Further studies are recommended to explore the effects of higher concentrations and long-term applications in clinical settings. Keywords: Clitoria ternatea extract, IL-1β modulation, antiphotoaging, photoprotective agents, herbal skincare.                                                   
Pharmacogenomics β-Blockers in Cardiovascular Disease: Implications for Blood Pressure and Clinical Outcomes Zulqifli, Iqbal; Malau, Jekmal; Aditya, Fitra Ari; Nursyafillah, Rizki Noval; Harbulcholizi, Luthfi; Rahmasari, Ratika; Raekiansyah, Muhareva; Hermosaningtyas, Anastasia Aliesa
Indonesian Journal of Pharmaceutical Science and Technology Vol 13, No 2 (2026)
Publisher : Indonesian Journal of Pharmaceutical Science and Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/ijpst.v13i2.60681

Abstract

Hypertension is a chronic condition that increases the risk of cardiovascular disease and death. β-blockers, including atenolol, metoprolol, bisoprolol, and carvedilol, lower blood pressure by blocking adrenergic receptors. However, variations in response and side effects are often influenced by genetic differences that affect drug metabolism and action. This narrative review analyzes studies published between 2014 and 2024 in PubMed, ScienceDirect, and Google Scholar using keywords related to genetic variation, β-blockers, hypertension, pharmacogenetics, and polymorphisms. Original studies in English, clinical trials on genetic polymorphisms and β-blocker response were included; reviews and incomplete studies were excluded. Clinical outcomes included changes in systolic and diastolic blood pressure, heart rate, hypotension, aortic root z-score, LVOT gradient, NT-proBNP, and premature ventricular contractions, which were associated with polymorphisms in the ADRB1, ADRB2, ACY3, FGD5, SLC4A1, and SLC25A31 genes. Metabolic outcomes, impaired fasting glucose, new-onset diabetes, and melatonin metabolite changes were associated with variants in PRKCB, DPYS, PAH, and PLEKHH2. Most data came from European and North American populations, with limited representation from Asia, limiting generalizability. These findings support the use of pharmacogenomics to personalize β-blocker therapy and improve hypertension management, despite challenges related to high costs, limited infrastructure, the lack of clinical guidelines, and population heterogeneity.
Co-Authors Aditya, Fitra Ari Damayanti, Galih Sari Fany, Alfa Sofia Harbulcholizi, Luthfi Hermosaningtyas, Anastasia Aliesa Jekmal Malau Kresnantio, Febryan Fadhil Mahadewa, Narendra Lintang Muhareva Raekiansyah Rahmasari, Ratika Zulqifli, Iqbal